- Home
- MIY vs XOMA Comparison
MIY vs XOMA Comparison
Compare MIY & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIY | XOMA |
|---|---|---|
| Founded | N/A | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.5M | 308.6M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | MIY | XOMA |
|---|---|---|
| Price | $12.55 | $25.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $60.60 |
| AVG Volume (30 Days) | 66.8K | ★ 172.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $77.29 |
| Revenue Next Year | N/A | $29.30 |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.57 | $18.40 |
| 52 Week High | $12.77 | $39.92 |
Technical Indicators
Market Signals| Indicator | MIY | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 65.03 | 50.22 |
| Support Level | $10.95 | $23.71 |
| Resistance Level | $12.77 | $27.73 |
| Average True Range (ATR) | 0.23 | 1.28 |
| MACD | 0.02 | 0.26 |
| Stochastic Oscillator | 73.48 | 68.43 |
Price Performance
Historical ComparisonAbout MIY Blackrock MuniYield Michigan Quality Fund Inc.
Blackrock Muniyield Michigan Quality Fund Inc is a closed end fund. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.